{
  "symbol": "BLFS",
  "company_name": "Biolife Solutions",
  "ir_website": "https://investors.biolifesolutions.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary",
          "url": "https://investors.biolifesolutions.com/2024-11-14-BioLife-Solutions-Announces-6-1-million-Sale-of-its-Custom-Biogenic-Systems-Freezer-Subsidiary",
          "content": "[Skip to content](#content)\n\n  * [ MAIN SITE ](https://biolifesolutions.com)\n  * [ STORE ](https://shop.biolifesolutions.com)\n  * [Evidence Library](https://evidence.biolifesolutions.com/)\n  * [Investors](https://investors.biolifesolutions.com/welcome)\n\n\n\n[ ![BioLife Solutions Logo](images/biolife_logo.png) ](https://biolifesolutions.com)\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](#)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nMenu\n\n[Home](https://biolifesolutions.com/ \"Home\")\n\n[ Press Releases ](https://investors.biolifesolutions.com/press-releases \"Press Releases\")\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * Financials \n    * [Financials](https://investors.biolifesolutions.com/financials)\n    * [Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nPress Releases \n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * [ - Financials](https://investors.biolifesolutions.com/financials)\n    * [ - Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [ - SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\n![](images/logo_mark_only.png)\n\nInvestor Contact\n\nMedia & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 twichterman@biolifesolutions.com\n\nTransfer Agent\n\nBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 shareholder@broadridge.com\n\nInvestor Alerts\n\n[Register here](get-news-alerts-by-email) to receive email notifications with updates about our press releases, stock price, SEC filings and more.\n\n## Press Releases\n\nBioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary\n\n  * [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D408 \"Facebook Share\")\n  * [ ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D408 \"Linkedin Share\")\n  * [ ](https://twitter.com/share?url=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D408 \"Twitter Share\")\n  * [](#email \"email\")\n  * [](#print \"print\")\n  * [](https://investors.biolifesolutions.com/2024-11-14-BioLife-Solutions-Announces-6-1-million-Sale-of-its-Custom-Biogenic-Systems-Freezer-Subsidiary?asPDF=1 \"pdf\")\n\n\n\n_Completes the Company's strategic move away from capital equipment businesses_\n\nBOTHELL, Wash., Nov. 14, 2024 /[PRNewswire](http://www.prnewswire.com/)/ -- [**BioLife Solutions**](https://c212.net/c/link/?t=0&l=en&o=4303699-1&h=2733711653&u=https%3A%2F%2Fwww.biolifesolutions.com%2F&a=BioLife+Solutions)**, Inc. (NASDAQ:[BLFS](https://www.prnewswire.com/news-releases/biolife-solutions-announces-6-1-million-sale-of-its-custom-biogenic-systems-freezer-subsidiary-302306361.html#financial-modal))** (\"BioLife\" or the \"Company\"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. (\"Custom Biogenic Systems\" or \"CBS\"), for $6.1 million in cash.\n\n\"We have now completed the divestiture of all our freezer and related businesses, which began with the sale of Global Cooling in April. The sale of CBS aligns with our strategic refocus on our proprietary, higher-margin, recurring-revenue cell processing products, and away from our capital equipment freezer and storage businesses that previously included Stirling, SciSafe and CBS,\" commented Roderick de Greef, Chairman and CEO of BioLife Solutions.\n\n**_About BioLife Solutions_**\n\nBioLife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy (CGT) market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, storage and distribution. For more information, please visit [www.biolifesolutions.com](https://c212.net/c/link/?t=0&l=en&o=4303699-1&h=2161378329&u=https%3A%2F%2Fwww.biolifesolutions.com%2F&a=www.biolifesolutions.com), and follow BioLife on [LinkedIn](https://c212.net/c/link/?t=0&l=en&o=4303699-1&h=1578841736&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbiolife-solutions-inc-&a=LinkedIn) and [X](https://c212.net/c/link/?t=0&l=en&o=4303699-1&h=3479957982&u=https%3A%2F%2Ftwitter.com%2Fbiolifesol&a=X).\n\n**_Cautions Regarding Forward Looking Statements_**\n\nCertain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"plans,\" \"expects,\" \"believes,\" \"anticipates,\" \"designed,\" and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at [www.sec.gov](http://www.sec.gov/). Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.\n\n**_Media & Investor Relations_** _At the Company_ Troy Wichterman Chief Financial Officer (425) 402-1400 _twichterman@biolifesolutions.com_\n\n_Investors_ Alliance Advisors IR Jody Cain (310) 691-7100 _jcain@allianceadvisors.com_\n\nSOURCE BioLife Solutions, Inc.\n"
        },
        {
          "title": "BioLife Solutions Reports Third Quarter 2024 Financial Results",
          "url": "https://investors.biolifesolutions.com/2024-11-12-BioLife-Solutions-Reports-Third-Quarter-2024-Financial-Results",
          "content": "[Skip to content](#content)\n\n  * [ MAIN SITE ](https://biolifesolutions.com)\n  * [ STORE ](https://shop.biolifesolutions.com)\n  * [Evidence Library](https://evidence.biolifesolutions.com/)\n  * [Investors](https://investors.biolifesolutions.com/welcome)\n\n\n\n[ ![BioLife Solutions Logo](images/biolife_logo.png) ](https://biolifesolutions.com)\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](#)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nMenu\n\n[Home](https://biolifesolutions.com/ \"Home\")\n\n[ Press Releases ](https://investors.biolifesolutions.com/press-releases \"Press Releases\")\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * Financials \n    * [Financials](https://investors.biolifesolutions.com/financials)\n    * [Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nPress Releases \n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * [ - Financials](https://investors.biolifesolutions.com/financials)\n    * [ - Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [ - SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\n![](images/logo_mark_only.png)\n\nInvestor Contact\n\nMedia & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 twichterman@biolifesolutions.com\n\nTransfer Agent\n\nBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 shareholder@broadridge.com\n\nInvestor Alerts\n\n[Register here](get-news-alerts-by-email) to receive email notifications with updates about our press releases, stock price, SEC filings and more.\n\n## Press Releases\n\nBioLife Solutions Reports Third Quarter 2024 Financial Results\n\n  * [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D407 \"Facebook Share\")\n  * [ ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D407 \"Linkedin Share\")\n  * [ ](https://twitter.com/share?url=https%3A%2F%2Finvestors.biolifesolutions.com%2Findex.php%3Fs%3D43%26item%3D407 \"Twitter Share\")\n  * [](#email \"email\")\n  * [](#print \"print\")\n  * [](https://investors.biolifesolutions.com/2024-11-12-BioLife-Solutions-Reports-Third-Quarter-2024-Financial-Results?asPDF=1 \"pdf\")\n\n\n\n_Cell Processing revenue grew_ _6%__sequentially to_ _$19.0 million ; 43% increase compared to 2023_\n\n_GAAP gross margin of_ _51%__and non-GAAP adjusted gross margin of_ _54%_\n\n_GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%_\n\n_Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture_\n\n_Conference call begins at 4:30 p.m. Eastern time today_\n\nBOTHELL, Wash., Nov. 12, 2024 /[PRNewswire](http://www.prnewswire.com/)/ -- **_BioLife Solutions, Inc._****(Nasdaq: BLFS)** (\"BioLife\" or the \"Company\"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (\"CGT\") market, today announced financial results for the three and nine months ended September 30, 2024 and updated revenue guidance for 2024.\n\n[ ![BioLife Solutions New Logo 2021 \\(PRNewsfoto/BioLife Solutions, Inc.\\)](https://mma.prnewswire.com/media/1533257/BioLife_Solutions_Logo.jpg) ](https://mma.prnewswire.com/media/1533257/BioLife_Solutions_Logo.html)\n\n\"I'm pleased to report our fourth consecutive quarter of sequential Cell Processing revenue growth and expansion of adjusted gross and adjusted EBTIDA margins,\" said Roderick de Greef, BioLife Chairman and CEO. \"With Q3 now in the books and with good visibility into Q4, we are increasing our projected 2024 Cell Processing revenues by $2 million above our previous guidance. Adjusting for the absence of revenue from the sale of our SciSafe biostorage business, this puts the total revenue for 2024 in the range of $98.0 to $100.0 million.\"\n\nde Greef continued, \"The sale of our SciSafe biostorage business for $73 million in cash is a major step in our efforts to focus our energy and capital allocation toward our proprietary, high growth and high margin cell processing products. BioLife is now a pure play enabler of CGT's globally and with a fortified balance sheet, and a streamlined operational environment, we can better focus on our unique biopreservation market leadership position to drive revenue growth and profitability in 2025 and beyond.\"\n\n**_Third Quarter 2024 Business Highlights_**\n\n  * Processed 16 new U.S. FDA Master File cross references for our biopreservation media, bringing the cumulative total processed to 744.\n  * Based on two additional regulatory approvals in the third quarter, our biopreservation media is embedded in 17 unique commercial CGT's as of September 30, 2024, with an expectation that 6 additional product approvals, geographic expansions, or new indications will occur in the next 12 months.\n  * On November 12, 2024, we completed the sale of SciSafe Holdings, Inc. (\"SciSafe\"), a previously wholly owned biostorage and services subsidiary, for $73.0 million in cash.\n\n\n\n**_Third Quarter 2024 Financial Performance_**\n\nBioLife Solutions is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife Solutions is presenting adjusted (non-GAAP) metrics on a consolidated basis and also presenting its non-GAAP financial metrics excluding the financial results of GCI from its consolidated results. Reconciliations of GAAP to non-GAAP metrics appear at the end of this news release.\n\nREVENUE\n\n  * Total revenue for the third quarter of 2024 was $30.6 million, an increase of $7.0 million, or 30%, from $23.6 million for the third quarter of 2023 and up $2.2 million, or 8%, sequentially from the second quarter of 2024.\n    * Cell Processing platform revenue was $19.0 million, an increase of $5.7 million, or 43%, from the same period in 2023 and up $1.0 million, or 6%, sequentially from the second quarter of 2024.\n    * Biostorage Services platform revenue was $7.5 million, an increase of $0.9 million, or 14%, from the same period in 2023 and up $0.6 million, or 8%, sequentially from the second quarter of 2024.\n    * Freezers and Thaw Systems platform revenue was $4.0 million, an increase of $0.4 million, or 11%, from the same period in 2023 and up $0.6 million, or 19%, sequentially from the second quarter of 2024.\n  * Total revenue for the nine months ended September 30, 2024 was $85.7 million, an increase of $3.7 million, or 4%, from the same period in 2023.\n    * Cell Processing platform revenue for the nine months ended September 30, 2024 was $53.2 million, an increase of $2.2 million, or 4%, from the same period in 2023.\n    * Biostorage Services platform revenue was $21.6 million, an increase of $2.3 million, or 12%, from the same period in 2023 .\n    * Freezers and Thaw Systems platform revenue was $10.9 million, a decrease of $0.9 million, or 7%, from the same period in 2023.\n\n\n\nGROSS MARGIN\n\n  * Gross margin (GAAP) for the third quarter of 2024 was 51% compared with 48% for the third quarter of 2023. Adjusted gross margin (non-GAAP) for the third quarter of 2024 was 54% compared with 44% for the third quarter of 2023.\n  * Gross margin (GAAP) for the nine months ended September 30, 2024 was 51% compared with 42% for the same period in 2023. Adjusted gross margin (non-GAAP) for the nine months ended September 30, 2024 was 53% compared with 46% for the same period in 2023.\n\n\n\nOPERATING LOSS FROM CONTINUING OPERATIONS\n\n  * Operating loss from continuing operations (GAAP) for the third quarter of 2024 was $1.6 million compared with $15.5 million for the third quarter of 2023. Adjusted operating loss from continuing operations (non-GAAP) for the third quarter of 2024 was $0.6 million compared with $8.3 million for the third quarter of 2023.\n  * Operating loss from continuing operations (GAAP) for the nine months ended September 30, 2024 was $8.5 million compared with $34.7 million for the same period in 2023. Adjusted operating loss from continuing operations (non-GAAP) for the nine months ended September 30, 2024 was $5.8 million compared with $19.7 million for the same period in 2023.\n\n\n\nNET LOSS FROM CONTINUING OPERATIONS\n\n  * Net loss from continuing operations (GAAP) for the third quarter of 2024 was $1.7 million compared with $15.8 million for the third quarter of 2023. Adjusted net loss from continuing operations (non-GAAP) for the third quarter of 2024 was $0.8 million compared with $8.5 million for the third quarter of 2023.\n  * Net loss from continuing operations (GAAP) for the nine months ended September 30, 2024 was $13.1 million, which includes a $4.1 million write-off of our iVexSol equity investment, compared with $30.0 million for the same period in 2023. Adjusted net loss from continuing operations (non-GAAP) for the nine months ended September 30, 2024 was $6.2 million compared with $20.0 million for the same period in 2023.\n\n\n\nLOSS PER SHARE FROM CONTINUING OPERATIONS\n\n  * Loss per share from continuing operations (GAAP) for the third quarter of 2024 was $0.04 compared with $0.36 for the third quarter of 2023.\n  * Loss per share from continuing operations (GAAP) for the nine months ended September 30, 2024 was $0.28 compared with $0.69 for the same period in 2023.\n\n\n\nADJUSTED EBITDA\n\n  * Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2024 was $6.1 million, or 20% of revenue, compared with $1.4 million, or 6% of revenue, for the third quarter of 2023.\n  * Adjusted EBITDA, a non-GAAP measure, for the nine months ended September 30, 2024 was $14.6 million, or 17% of revenue, compared with $5.2 million, or 6% of revenue, for the same period in 2023.\n  * CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES\n  * Cash, cash equivalents, and marketable securities as of September 30, 2024, were $39.3 million.\n\n\n\n_(As a result of showing amounts in millions, rounding difference may exist in the percentages above.)_\n\n**_2024 Revenue Guidance_**\n\nBioLife Solutions is revising its 2024 revenue guidance to $98.0 million to $100.0 million from prior guidance of $99.0 million to $101.0 million primarily to reflect the revenue impact of the divestiture of SciSafe on November 12, 2024. This guidance also reflects updated expectations for BioLife's Cell Processing product line and Biostorage and Services, which includes results from its ThawSTAR® product line and does not include revenue from the freezer product line (GCI and CBS) or SciSafe after November 12, 2024.\n\n  * Cell Processing platform revenue: Increased to $72.0 million to $73.0 million from prior guidance of $70.0 million to $71.0 million. The revised guidance represents an increase of 9% to 11% compared with 2023. Compared with the annualized run rate for the second half of 2023, the revised guidance reflects growth of 28% to 30%.\n  * Biostorage Services platform revenue: Revised to $26.0 million to $27.0 million from prior guidance of $29.0 million to $30.0 million. The revised guidance represents a decrease of 7% to 4% compared with 2023 due to the sale of SciSafe on November 12, 2024. This platform includes the ThawSTAR automated thawing product line. Excluding ThawSTAR, the growth rate is 1% to 4%.\n\n\n\nManagement expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024.\n\n**_Conference Call & Webcast_**\n\nManagement will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).\n\nTo access the webcast, log onto the Investor Relations page of the BioLife Solutions website at  _[https://www.biolifesolutions.com/earnings](https://c212.net/c/link/?t=0&l=en&o=4301157-1&h=3338469898&u=https%3A%2F%2Fwww.biolifesolutions.com%2Fearnings&a=https%3A%2F%2Fwww.biolifesolutions.com%2Fearnings)._ In addition, the conference call will be accessible by dialing toll-free 833-630-0431 or 412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on  _[https://www.biolifesolutions.com/](https://c212.net/c/link/?t=0&l=en&o=4301157-1&h=2847936771&u=https%3A%2F%2Fwww.biolifesolutions.com%2F&a=https%3A%2F%2Fwww.biolifesolutions.com%2F)_ for 90 days.\n\n**_About BioLife Solutions_**\n\nBioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit _[www.biolifesolutions.com](https://c212.net/c/link/?t=0&l=en&o=4301157-1&h=1270194283&u=https%3A%2F%2Fwww.biolifesolutions.com%2F&a=www.biolifesolutions.com)_ , and follow BioLife on [ _LinkedIn_](https://c212.net/c/link/?t=0&l=en&o=4301157-1&h=2606720187&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbiolife-solutions-inc-%2F&a=LinkedIn) and [_X_](https://c212.net/c/link/?t=0&l=en&o=4301157-1&h=2585638241&u=https%3A%2F%2Fx.com%2Fbiolifesol&a=X).\n\n**_Cautions Regarding Forward Looking Statements_**\n\n_Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"plans,\" \"expects,\" \"believes,\" \"anticipates,\" \"designed,\" and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at[www.sec.gov](http://www.sec.gov). Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events._\n\n**Non-GAAP Measures of Financial Performance**\n\n_To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release._\n\n_We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information._\n\n_While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP._\n\n**_Media & Investor Relations_**\n\n_At the Company_\n\nTroy WichtermanChief Financial Officer(425) 402-1400 _twichterman@biolifesolutions.com_\n\n_Investors_\n\nLHA Investor RelationsJody Cain(310) 691-7100 _jcain@lhai.com_\n\nOn April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (\"Global Cooling\"), to GCI Holdings Company, LLC, an Ohio limited liability company (\"GCI Holdings\") pursuant to a Stock Purchase Agreement (the \"Purchase Agreement\"), by and between the Company and GCI Holdings (the \"Global Cooling Divestiture\"). Upon the execution of the Purchase Agreement, on April 17, 2024, Global Cooling business is presented in the unaudited condensed financial statements as a discontinued operation for all periods presented. All amounts included in this earnings release relate to continuing operations unless otherwise noted.\n\nView News Release Full Screen**BIOLIFE SOLUTIONS, INC.** **CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** **(Unaudited, amounts in thousands, except share and per share amounts)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands, except per share and share data)** | **2024** | **2023** | **2024** | **2023**  \nProduct revenue | $ 23,457 | $ 17,137 | $ 64,624 | $ 63,444  \nService revenue | 4,660 | 4,377 | 14,173 | 12,573  \nRental revenue | 2,454 | 2,059 | 6,881 | 5,975  \nTotal product, rental, and service revenue | 30,571 | 23,573 | 85,678 | 81,992  \nCosts and operating expenses:  \nCost of product, rental, and service revenue (exclusive of Intangible asset amortization) | $ 14,276 | $ 11,578 | $ 40,278 | $ 44,989  \nGeneral and administrative | 11,351 | 10,813 | 33,953 | 37,568  \nSales and marketing | 3,543 | 4,876 | 10,401 | 12,731  \nResearch and development | 2,050 | 3,739 | 6,827 | 10,772  \nAsset impairment charges | — | 8,310 | — | 8,310  \nIntangible asset amortization | 910 | 1,312 | 2,734 | 4,135  \nChange in fair value of contingent consideration | — | (1,580) | — | (1,778)  \nTotal operating expenses | 32,130 | 39,048 | 94,193 | 116,727  \nOperating loss | (1,559) | (15,475) | (8,515) | (34,735)  \nOther (expense) income:  \nChange in fair value of equity investments | — | — | (4,074) | —  \nGain on settlement of Global Cooling escrow | — | — | — | 5,115  \nInterest expense, net | (267) | (449) | (796) | (1,216)  \nOther income | 95 | 235 | 417 | 1,002  \nTotal other (expense) income, net | (172) | (214) | (4,453) | 4,901  \nLoss before income tax benefit (expense) | (1,731) | (15,689) | (12,968) | (29,834)  \nIncome tax benefit (expense) | 28 | (115) | (93) | (209)  \nNet loss from continuing operations | $ (1,703) | $ (15,804) | $ (13,061) | $ (30,043)  \nDiscontinued operations:  \nLoss from discontinued operations | — | (13,328) | (19,572) | (22,999)  \nIncome tax expense | — | — | (10) | (3)  \nLoss from discontinued operations | $ — | $ (13,328) | $ (19,582) | $ (23,002)  \nNet loss | $ (1,703) | $ (29,132) | $ (32,643) | $ (53,045)  \nLoss from continuing operations, attributable to common shareholders:  \nBasic and Diluted | $ (1,703) | $ (15,804) | $ (13,061) | $ (30,043)  \nLoss from discontinued operations, attributable to common shareholders:  \nBasic and Diluted | $ — | $ (13,328) | $ (19,582) | $ (23,002)  \nLoss per share from continuing operations, attributable to common shareholders:  \nBasic and Diluted | $ (0.04) | $ (0.36) | $ (0.28) | $ (0.69)  \nLoss per share from discontinued operations, attributable to common shareholders:  \nBasic and Diluted | $ — | $ (0.31) | $ (0.43) | $ (0.53)  \nNet loss attributable to common shareholders:  \nBasic and Diluted | $ (1,703) | $ (29,132) | $ (32,643) | $ (53,045)  \nNet loss per share attributable to common shareholders:  \nBasic and Diluted | $ (0.04) | $ (0.67) | $ (0.71) | $ (1.22)  \nWeighted average shares used to compute loss per share attributable to common shareholders:  \nBasic and Diluted | 46,175,345 | 43,570,438 | 45,871,715 | 43,348,412  \n  \n**BIOLIFE SOLUTIONS, INC.** **CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended** **September 30,** | **Nine Months Ended** **September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nNet loss | $ (1,703) | $ (29,132) | $ (32,643) | $ (53,045)  \nOther comprehensive income (loss) | 347 | (161) | 137 | 19  \nComprehensive loss | $ (1,356) | $ (29,293) | $ (32,506) | $ (53,026)  \n  \n**BIOLIFE SOLUTIONS, INC.** **CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION** **(Unaudited, amounts in thousands)**  \n---  \n**September 30,** | **December 31,**  \n**(In thousands)** | **2024** | **2023**  \nCash, cash equivalents, and marketable securities | $ 39,256 | $ 50,184  \nWorking capital | 57,217 | 78,426  \nCurrent assets | 89,383 | 105,235  \nCurrent assets, discontinued operations | — | 15,369  \nCurrent liabilities | 32,166 | 29,382  \nCurrent liabilities, discontinued operations | — | 12,796  \nTotal assets | 381,652 | 412,714  \nLong-term obligations, discontinued operations | — | 1,027  \nLong-term obligations | 24,025 | 31,846  \nAccumulated deficit(1) | (347,560) | (314,917)  \nTotal shareholders' equity | 325,461 | 337,663  \n  \n(1) During the three months ended March 31, 2024, we determined that an immaterial error existed in our previously issued consolidated financial statements related to stock compensation expense on unvested shares of market-based awards of certain employees upon their termination. Our Accumulated deficit was impacted by the error by $1.6 million and was corrected within our Quarterly Report on Form 10-Q filed for the three months ended March 31, 2024.  \n---  \n  \n**BIOLIFE SOLUTIONS, INC.** **CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION** **(Unaudited, amounts in thousands)**  \n---  \n**Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023**  \nNet cash provided by (used in) operating activities | $ 6,786 | $ (14,809)  \nNet cash (used in) provided by investing activities | (15,337) | 13,880  \nNet cash (used in) provided by financing activities | (2,697) | 750  \nEffects of currency translation | (29) | (28)  \nNet decrease in cash, cash equivalents, and restricted cash | $ (11,277) | $ (207)  \n  \nAs a result of the Company's divestiture of Global Cooling during the quarter, several financial metrics were re-forecasted to more closely align with continuing operations. During this process, several non-GAAP measures were adjusted, resulting in differences between previously reported non-GAAP results on a continuing operations basis. All adjusted items are designated with a (*) symbol.\n\n**BIOLIFE SOLUTIONS, INC.** **RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP ADJUSTED GROSS MARGIN** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nTotal revenues | $ 30,571 | $ 23,573 | $ 85,678 | $ 81,992  \nCost of revenues | (14,276) | (11,578) | (40,278) | (44,989)  \nCOGS intangible asset amortization | (577) | (733) | (1,736) | (2,199)  \nGROSS PROFIT | $ 15,718 | $ 11,262 | $ 43,664 | $ 34,804  \nGROSS MARGIN | 51 % | 48 % | 51 % | 42 %  \nADJUSTMENTS TO GROSS PROFIT:  \nInventory reserve costs | 247 | (1,623) | 247 | 562  \nLoss (gain) on disposal of assets* | 4 | — | (44) | —  \nIntangible asset amortization | 577 | 733 | 1,736 | 2,199  \nADJUSTED GROSS PROFIT | $ 16,546 | $ 10,372 | $ 45,603 | $ 37,565  \nADJUSTED GROSS MARGIN | 54 % | 44 % | 53 % | 46 %  \n  \nView News Release Full Screen**BIOLIFE SOLUTIONS, INC.** **RECONCILIATION OF GAAP OPERATING EXPENSES FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED OPERATING EXPENSES FROM CONTINUING OPERATIONS** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nOPERATING EXPENSES FROM CONTINUING OPERATIONS | $ 32,130 | $ 39,048 | $ 94,193 | $ 116,727  \nADJUSTMENTS TO OPERATING EXPENSES FROM CONTINUING OPERATIONS:  \nCost of product, rental, and service revenues | (14,276) | (11,578) | (40,278) | (44,989)  \nAcquisition and divestiture costs | (442) | (250) | (833) | (3,226)  \nSeverance costs | — | (493) | — | (493)  \nIntangible asset amortization | (910) | (1,312) | (2,734) | (4,135)  \nLoss on disposal of assets | (4) | (11) | 96 | (39)  \nChange in fair value of contingent consideration | — | 1,580 | — | 1,778  \nOther income | 679 | — | 979 | —  \nAsset impairment charges | — | (8,310) | — | (8,310)  \nADJUSTED OPERATING EXPENSES FROM CONTINUING OPERATIONS | $ 17,177 | $ 18,674 | $ 51,423 | $ 57,313  \n  \nView News Release Full Screen**BIOLIFE SOLUTIONS, INC.** **RECONCILIATION OF GAAP OPERATING LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nOPERATING LOSS FROM CONTINUING OPERATIONS | $ (1,559) | $ (15,475) | $ (8,515) | $ (34,735)  \nADJUSTMENTS TO OPERATING LOSS FROM CONTINUING OPERATIONS  \nInventory reserve costs | 247 | (1,623) | 247 | 562  \nAcquisition and divestiture costs | 442 | 250 | 833 | 3,226  \nSeverance costs | — | 493 | — | 493  \nIntangible asset amortization | 910 | 1,312 | 2,734 | 4,135  \nLoss (gain) on disposal of assets | 4 | 11 | (96) | 39  \nChange in fair value of contingent consideration | — | (1,580) | — | (1,778)  \nOther income | (679) | — | (979) | —  \nAsset impairment charges | — | 8,310 | — | 8,310  \nADJUSTED OPERATING LOSS FROM CONTINUING OPERATIONS | $ (635) | $ (8,302) | $ (5,776) | $ (19,748)  \n  \nView News Release Full Screen**BIOLIFE SOLUTIONS, INC.** **RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED NET LOSS FROM CONTINUING OPERATIONS** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nNET LOSS FROM CONTINUING OPERATIONS | $ (1,703) | $ (15,804) | $ (13,061) | $ (30,043)  \nADJUSTMENTS TO NET LOSS FROM CONTINUING OPERATIONS  \nInventory reserve costs | 247 | (1,623) | 247 | 562  \nAcquisition and divestiture costs | 442 | 250 | 833 | 3,226  \nSeverance costs | — | 493 | — | 493  \nIntangible asset amortization | 910 | 1,312 | 2,734 | 4,135  \nLoss (gain) on disposal of assets | 4 | 11 | (96) | 39  \nChange in fair value of equity investments | — | — | 4,074 | —  \nChange in fair value of contingent consideration | — | (1,580) | — | (1,778)  \nOther income | (679) | — | (979) | —  \nIncome tax (benefit) expense | (28) | 115 | 93 | 209  \nGain on settlement of Global Cooling escrow | — | — | — | (5,115)  \nAsset impairment charges | — | 8,310 | — | 8,310  \nADJUSTED NET LOSS FROM CONTINUING OPERATIONS | $ (807) | $ (8,516) | $ (6,155) | $ (19,962)  \n  \nView News Release Full Screen**BIOLIFE SOLUTIONS, INC.** **RECONCILIATION OF GAAP NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA FROM CONTINUING OPERATIONS** **(Unaudited, amounts in thousands)**  \n---  \n**Three Months Ended****September 30,** | **Nine Months Ended****September 30,**  \n**(In thousands)** | **2024** | **2023** | **2024** | **2023**  \nNET LOSS FROM CONTINUING OPERATIONS | $ (1,703) | $ (15,804) | $ (13,061) | $ (30,043)  \nADJUSTMENTS:  \nInterest expense, net | 267 | 449 | 796 | 1,216  \nAccretion of available-for-sale investments* | (88) | (309) | (408) | (1,048)  \nIncome tax (benefit) expense | (28) | 115 | 93 | 209  \nDepreciation | 1,407 | 1,788 | 4,305 | 5,261  \nIntangible asset amortization | 910 | 1,312 | 2,734 | 4,135  \nEBITDA | $ 765 | $ (12,449) | $ (5,541) | $ (20,270)  \nOTHER ADJUSTMENTS:  \nShare-based compensation (non-cash) | 5,324 | 7,984 | 16,022 | 19,715  \nInventory reserve costs | 247 | (1,623) | 247 | 562  \nAcquisition and divestiture costs | 442 | 250 | 833 | 3,226  \nSeverance costs | — | 493 | — | 493  \nLoss (gain) on disposal of assets | 4 | 11 | (96) | 39  \nChange in fair value of equity investments | — | — | 4,074 | —  \nChange in fair value of contingent consideration | — | (1,580) | — | (1,778)  \nOther income | (679) | — | (979) | —  \nGain on settlement of Global Cooling escrow | — | — | — | (5,115)  \nAsset impairment charges | — | 8,310 | — | 8,310  \nADJUSTED EBITDA FROM CONTINUING OPERATIONS | $ 6,103 | $ 1,396 | $ 14,560 | $ 5,182  \n% of Revenue | 20 % | 6 % | 17 % | 6 %  \n  \nSOURCE BioLife Solutions, Inc.\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financials",
          "url": "https://investors.biolifesolutions.com/financials",
          "content": "[Skip to content](#content)\n\n  * [ MAIN SITE ](https://biolifesolutions.com)\n  * [ STORE ](https://shop.biolifesolutions.com)\n  * [Evidence Library](https://evidence.biolifesolutions.com/)\n  * [Investors](https://investors.biolifesolutions.com/welcome)\n\n\n\n[ ![BioLife Solutions Logo](images/biolife_logo.png) ](https://biolifesolutions.com)\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](#)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nMenu\n\n[Home](https://biolifesolutions.com/ \"Home\")\n\n[ Financials ](financials \"Financials\")\n\nFinancials\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * Financials \n    * [Financials](https://investors.biolifesolutions.com/financials)\n    * [Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nFinancials \n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * [ - Financials](https://investors.biolifesolutions.com/financials)\n    * [ - Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [ - SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\n![](images/logo_mark_only.png)\n\nInvestor Contact\n\nMedia & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 twichterman@biolifesolutions.com\n\nTransfer Agent\n\nBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 shareholder@broadridge.com\n\nInvestor Alerts\n\n[Register here](get-news-alerts-by-email) to receive email notifications with updates about our press releases, stock price, SEC filings and more.\n\n## Financials\n\nNASDAQBLFS\n\nCreated with Highstock 1.3.5\n\nLoading...\n\n1dy\n\n1mo\n\n6mo\n\n1yr\n\n5yr\n\n## Per Share Data\n\nEarnings (TTM)| ($1.05)  \n---|---  \nSales (TTM)| $3.09  \nBook Value (MRQ)| $7.02  \nCash Flow (TTM)| $0.20  \nCash (MRQ)| $0.74  \n  \nNASDAQBLFS\n\nBeta| 1.88  \n---|---  \nShares Outstanding| 46.4M  \nAverage Volume (10 days)| 644.1K  \nQtrly Dividend (Ann. Yield)| -- (--)  \n  \n## Recent Insider Transactions\n\nMathew Aby EVP & Chief Scientific Officer| (17,604) Sell Nov 18, 2024  \n---|---  \nMathew Aby EVP & Chief Scientific Officer| (15,000) Sell Nov 15, 2024  \nMathew Aby EVP & Chief Scientific Officer| (10,000) Sell Nov 15, 2024  \nMathew Aby EVP & Chief Scientific Officer| (123) Sell Nov 12, 2024  \nFoster Karen Chief Quality Officer| (66) Sell Nov 12, 2024  \n  \n## Recent SEC Filings\n\n[4](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759141&type=HTML&symbol=BLFS&cdn=08cf25dc43bb6589e449b09ba2ce40b4&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29 \"HTML\") Insider Buy/Sell| Nov 29, 2024  \n---|---  \n[4](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759131&type=HTML&symbol=BLFS&cdn=88b65de517f8c66aaa9dd36518183bbf&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29 \"HTML\") Insider Buy/Sell| Nov 29, 2024  \n[4](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759142&type=HTML&symbol=BLFS&cdn=1a35ea690051a861def7a4439e2f93d5&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29 \"HTML\") Insider Buy/Sell| Nov 29, 2024  \n[4](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759132&type=HTML&symbol=BLFS&cdn=feb85eabfd0609313e4e1fc57872afab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29 \"HTML\") Insider Buy/Sell| Nov 29, 2024  \n[4](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759127&type=HTML&symbol=BLFS&cdn=f171c79707e5f1a95aedd07d60346198&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29 \"HTML\") Insider Buy/Sell| Nov 29, 2024  \n  \n## Analyst Views\n\nCurrent Mean Recommendation| Strong Buy  \n---|---  \nStrong Buy| 10  \n---|---  \nBuy| 0  \nHold| 0  \nUnderperform| 0  \nSell| 0  \n  \nCurrency in USD.Quote data delayed by at least 15 minutes.Earnings and Analyst data provided by Zacks.Insiders data provided by Morningstar.\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://investors.biolifesolutions.com/analyst-coverage",
          "content": "[Skip to content](#content)\n\n  * [ MAIN SITE ](https://biolifesolutions.com)\n  * [ STORE ](https://shop.biolifesolutions.com)\n  * [Evidence Library](https://evidence.biolifesolutions.com/)\n  * [Investors](https://investors.biolifesolutions.com/welcome)\n\n\n\n[ ![BioLife Solutions Logo](images/biolife_logo.png) ](https://biolifesolutions.com)\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](#)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nMenu\n\n[Home](https://biolifesolutions.com/ \"Home\")\n\n[ Financials ](financials \"Financials\")\n\nAnalyst Coverage\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * Financials \n    * [Financials](https://investors.biolifesolutions.com/financials)\n    * [Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nAnalyst Coverage \n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * [ - Financials](https://investors.biolifesolutions.com/financials)\n    * [ - Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [ - SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\n![](images/logo_mark_only.png)\n\nInvestor Contact\n\nMedia & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 twichterman@biolifesolutions.com\n\nTransfer Agent\n\nBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 shareholder@broadridge.com\n\nInvestor Alerts\n\n[Register here](get-news-alerts-by-email) to receive email notifications with updates about our press releases, stock price, SEC filings and more.\n\n## Analyst Coverage\n\nBelow is a list of individual analysts that we are aware of that currently follow BioLife Solutions. \n\n_Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent BioLife Solutions or its management team. BioLife Solutions is under no obligation to update this list, thus it may not be complete or up to date._\n\nFirm | Analyst  \n---|---  \nBenchmark | Robert Wasserman  \nTD Cowen | Brendan Smith  \nCraig-Hallum | Matt G. Hewitt  \nH.C. Wainwright | Yi Chen  \nJefferies | Matthew Stanton  \nKeyBanc | Paul Knight, CFA   \nLake Street | Thomas Flaten  \nMaxim Group | Jason McCarthy, Ph.D.  \nNorthland Securities | Carl Byrnes  \nStephens | Jacob Johnson\n"
        },
        {
          "title": "SEC Filings",
          "url": "https://investors.biolifesolutions.com/SEC-filings",
          "content": "[Skip to content](#content)\n\n  * [ MAIN SITE ](https://biolifesolutions.com)\n  * [ STORE ](https://shop.biolifesolutions.com)\n  * [Evidence Library](https://evidence.biolifesolutions.com/)\n  * [Investors](https://investors.biolifesolutions.com/welcome)\n\n\n\n[ ![BioLife Solutions Logo](images/biolife_logo.png) ](https://biolifesolutions.com)\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](#)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nMenu\n\n[Home](https://biolifesolutions.com/ \"Home\")\n\n[ Financials ](financials \"Financials\")\n\nSEC Filings\n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * Financials \n    * [Financials](https://investors.biolifesolutions.com/financials)\n    * [Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\nSEC Filings \n\n  * [Investor Home](https://investors.biolifesolutions.com/welcome)\n  * [Governance](https://investors.biolifesolutions.com/corporate-governance)\n  * [Press Releases](https://investors.biolifesolutions.com/press-releases)\n  * [Financials](financials)\n    * [ - Financials](https://investors.biolifesolutions.com/financials)\n    * [ - Analyst Coverage](https://investors.biolifesolutions.com/analyst-coverage)\n    * [ - SEC Filings](https://investors.biolifesolutions.com/SEC-filings)\n  * [Stock Information](https://investors.biolifesolutions.com/stock-information)\n  * [Investor Contact](https://investors.biolifesolutions.com/investor-contact)\n\n\n\n![](images/logo_mark_only.png)\n\nInvestor Contact\n\nMedia & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 twichterman@biolifesolutions.com\n\nTransfer Agent\n\nBroadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 shareholder@broadridge.com\n\nInvestor Alerts\n\n[Register here](get-news-alerts-by-email) to receive email notifications with updates about our press releases, stock price, SEC filings and more.\n\n## SEC Filings\n\nSelect the filing type and date range you wish to view from the drop-down menus below.\n\nNASDAQBLFS\n\nYear\n\nTrailing 12-Months\n\nView\n\nAll Filings\n\nForm| Description| Date| Format  \n---|---|---|---  \n4| Statement of changes in beneficial ownership of securities| Nov 29, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759141&type=HTML&symbol=BLFS&cdn=08cf25dc43bb6589e449b09ba2ce40b4&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759141&type=DOC&symbol=BLFS&cdn=08cf25dc43bb6589e449b09ba2ce40b4&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759141&type=PDF&symbol=BLFS&cdn=08cf25dc43bb6589e449b09ba2ce40b4&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759141&type=XLS&symbol=BLFS&cdn=08cf25dc43bb6589e449b09ba2ce40b4&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)  \n4| Statement of changes in beneficial ownership of securities| Nov 29, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759131&type=HTML&symbol=BLFS&cdn=88b65de517f8c66aaa9dd36518183bbf&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759131&type=DOC&symbol=BLFS&cdn=88b65de517f8c66aaa9dd36518183bbf&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759131&type=PDF&symbol=BLFS&cdn=88b65de517f8c66aaa9dd36518183bbf&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759131&type=XLS&symbol=BLFS&cdn=88b65de517f8c66aaa9dd36518183bbf&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)  \n4| Statement of changes in beneficial ownership of securities| Nov 29, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759142&type=HTML&symbol=BLFS&cdn=1a35ea690051a861def7a4439e2f93d5&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759142&type=DOC&symbol=BLFS&cdn=1a35ea690051a861def7a4439e2f93d5&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759142&type=PDF&symbol=BLFS&cdn=1a35ea690051a861def7a4439e2f93d5&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759142&type=XLS&symbol=BLFS&cdn=1a35ea690051a861def7a4439e2f93d5&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)  \n4| Statement of changes in beneficial ownership of securities| Nov 29, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759132&type=HTML&symbol=BLFS&cdn=feb85eabfd0609313e4e1fc57872afab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759132&type=DOC&symbol=BLFS&cdn=feb85eabfd0609313e4e1fc57872afab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759132&type=PDF&symbol=BLFS&cdn=feb85eabfd0609313e4e1fc57872afab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759132&type=XLS&symbol=BLFS&cdn=feb85eabfd0609313e4e1fc57872afab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)  \n4| Statement of changes in beneficial ownership of securities| Nov 29, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759127&type=HTML&symbol=BLFS&cdn=f171c79707e5f1a95aedd07d60346198&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759127&type=DOC&symbol=BLFS&cdn=f171c79707e5f1a95aedd07d60346198&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759127&type=PDF&symbol=BLFS&cdn=f171c79707e5f1a95aedd07d60346198&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318759127&type=XLS&symbol=BLFS&cdn=f171c79707e5f1a95aedd07d60346198&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-29)  \n8-K| Report of unscheduled material events or corporate event| Nov 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Report of unscheduled material events or corporate event in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318735611&type=HTML&symbol=BLFS&cdn=499a56c486989bb7cd240cae77521f4d&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Report of unscheduled material events or corporate event in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318735611&type=DOC&symbol=BLFS&cdn=499a56c486989bb7cd240cae77521f4d&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Report of unscheduled material events or corporate event in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318735611&type=PDF&symbol=BLFS&cdn=499a56c486989bb7cd240cae77521f4d&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Report of unscheduled material events or corporate event in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318735611&type=XLS&symbol=BLFS&cdn=499a56c486989bb7cd240cae77521f4d&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-20)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Report of unscheduled material events or corporate event in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Report of unscheduled material events or corporate event in XBLR file.](#)  \n4| Statement of changes in beneficial ownership of securities| Nov 19, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318733384&type=HTML&symbol=BLFS&cdn=4cdcae659d80b5a200fe7872e7681d30&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-19)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318733384&type=DOC&symbol=BLFS&cdn=4cdcae659d80b5a200fe7872e7681d30&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-19)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318733384&type=PDF&symbol=BLFS&cdn=4cdcae659d80b5a200fe7872e7681d30&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-19)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318733384&type=XLS&symbol=BLFS&cdn=4cdcae659d80b5a200fe7872e7681d30&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-19)  \n4| Statement of changes in beneficial ownership of securities| Nov 14, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724193&type=HTML&symbol=BLFS&cdn=2cef8e97699b1d4f691c266d8ca40a36&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724193&type=DOC&symbol=BLFS&cdn=2cef8e97699b1d4f691c266d8ca40a36&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724193&type=PDF&symbol=BLFS&cdn=2cef8e97699b1d4f691c266d8ca40a36&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724193&type=XLS&symbol=BLFS&cdn=2cef8e97699b1d4f691c266d8ca40a36&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)  \n4| Statement of changes in beneficial ownership of securities| Nov 14, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724172&type=HTML&symbol=BLFS&cdn=17e13cd1b09de1fcb552577a104169e0&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724172&type=DOC&symbol=BLFS&cdn=17e13cd1b09de1fcb552577a104169e0&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724172&type=PDF&symbol=BLFS&cdn=17e13cd1b09de1fcb552577a104169e0&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724172&type=XLS&symbol=BLFS&cdn=17e13cd1b09de1fcb552577a104169e0&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)  \n4| Statement of changes in beneficial ownership of securities| Nov 14, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724176&type=HTML&symbol=BLFS&cdn=da6b35e239cadaa9fa580564058b0133&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724176&type=DOC&symbol=BLFS&cdn=da6b35e239cadaa9fa580564058b0133&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724176&type=PDF&symbol=BLFS&cdn=da6b35e239cadaa9fa580564058b0133&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724176&type=XLS&symbol=BLFS&cdn=da6b35e239cadaa9fa580564058b0133&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)  \n4| Statement of changes in beneficial ownership of securities| Nov 14, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724177&type=HTML&symbol=BLFS&cdn=553e67eaa396118e6fc329e812aac66d&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724177&type=DOC&symbol=BLFS&cdn=553e67eaa396118e6fc329e812aac66d&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724177&type=PDF&symbol=BLFS&cdn=553e67eaa396118e6fc329e812aac66d&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318724177&type=XLS&symbol=BLFS&cdn=553e67eaa396118e6fc329e812aac66d&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-14)  \n10-Q| Quarterly report which provides a continuing view of a company's financial position| Nov 12, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Quarterly report which provides a continuing view of a company's financial position in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708832&type=HTML&symbol=BLFS&cdn=23df688c3839ad30b9bd932517e7c300&companyName=BioLife+Solutions+Inc.&formType=10-Q&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_doc.png)Open Quarterly report which provides a continuing view of a company's financial position in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708832&type=DOC&symbol=BLFS&cdn=23df688c3839ad30b9bd932517e7c300&companyName=BioLife+Solutions+Inc.&formType=10-Q&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Quarterly report which provides a continuing view of a company's financial position in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708832&type=PDF&symbol=BLFS&cdn=23df688c3839ad30b9bd932517e7c300&companyName=BioLife+Solutions+Inc.&formType=10-Q&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xls.png)Open Quarterly report which provides a continuing view of a company's financial position in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708832&type=XLS&symbol=BLFS&cdn=23df688c3839ad30b9bd932517e7c300&companyName=BioLife+Solutions+Inc.&formType=10-Q&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Quarterly report which provides a continuing view of a company's financial position in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Quarterly report which provides a continuing view of a company's financial position in XBLR file.](#)  \n8-K| Report of unscheduled material events or corporate event| Nov 12, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Report of unscheduled material events or corporate event in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708423&type=HTML&symbol=BLFS&cdn=acdc5911734a4e3b49b9e142ac90b3b8&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_doc.png)Open Report of unscheduled material events or corporate event in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708423&type=DOC&symbol=BLFS&cdn=acdc5911734a4e3b49b9e142ac90b3b8&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Report of unscheduled material events or corporate event in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708423&type=PDF&symbol=BLFS&cdn=acdc5911734a4e3b49b9e142ac90b3b8&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xls.png)Open Report of unscheduled material events or corporate event in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318708423&type=XLS&symbol=BLFS&cdn=acdc5911734a4e3b49b9e142ac90b3b8&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Report of unscheduled material events or corporate event in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Report of unscheduled material events or corporate event in XBLR file.](#)  \n8-K| Report of unscheduled material events or corporate event| Nov 12, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Report of unscheduled material events or corporate event in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318704284&type=HTML&symbol=BLFS&cdn=58315c5a8c0175b6ab9f0a9c91b00f85&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_doc.png)Open Report of unscheduled material events or corporate event in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318704284&type=DOC&symbol=BLFS&cdn=58315c5a8c0175b6ab9f0a9c91b00f85&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Report of unscheduled material events or corporate event in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318704284&type=PDF&symbol=BLFS&cdn=58315c5a8c0175b6ab9f0a9c91b00f85&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xls.png)Open Report of unscheduled material events or corporate event in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318704284&type=XLS&symbol=BLFS&cdn=58315c5a8c0175b6ab9f0a9c91b00f85&companyName=BioLife+Solutions+Inc.&formType=8-K&dateFiled=2024-11-12)[![](images/webdriver/fileicons/16/sec_xbrl.png)Open Report of unscheduled material events or corporate event in XBLR Viewer.](#)[![](images/webdriver/fileicons/16/sec_xbrl_download.png)Open Report of unscheduled material events or corporate event in XBLR file.](#)  \nSC 13G| Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions| Nov 08, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318699514&type=HTML&symbol=BLFS&cdn=6d8fb12b87cc211d15fbeb37cc7421ad&companyName=BioLife+Solutions+Inc.&formType=SC+13G&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_doc.png)Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318699514&type=DOC&symbol=BLFS&cdn=6d8fb12b87cc211d15fbeb37cc7421ad&companyName=BioLife+Solutions+Inc.&formType=SC+13G&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318699514&type=PDF&symbol=BLFS&cdn=6d8fb12b87cc211d15fbeb37cc7421ad&companyName=BioLife+Solutions+Inc.&formType=SC+13G&dateFiled=2024-11-08)[![](images/webdriver/fileicons/16/sec_xls.png)Open Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318699514&type=XLS&symbol=BLFS&cdn=6d8fb12b87cc211d15fbeb37cc7421ad&companyName=BioLife+Solutions+Inc.&formType=SC+13G&dateFiled=2024-11-08)  \n4| Statement of changes in beneficial ownership of securities| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683814&type=HTML&symbol=BLFS&cdn=3d9ffd87f56d81cb9b29f1ca6350ebb7&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683814&type=DOC&symbol=BLFS&cdn=3d9ffd87f56d81cb9b29f1ca6350ebb7&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683814&type=PDF&symbol=BLFS&cdn=3d9ffd87f56d81cb9b29f1ca6350ebb7&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683814&type=XLS&symbol=BLFS&cdn=3d9ffd87f56d81cb9b29f1ca6350ebb7&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)  \n4| Statement of changes in beneficial ownership of securities| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683809&type=HTML&symbol=BLFS&cdn=1f7a555c65de5ad5a6168651d006df16&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683809&type=DOC&symbol=BLFS&cdn=1f7a555c65de5ad5a6168651d006df16&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683809&type=PDF&symbol=BLFS&cdn=1f7a555c65de5ad5a6168651d006df16&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683809&type=XLS&symbol=BLFS&cdn=1f7a555c65de5ad5a6168651d006df16&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)  \n4| Statement of changes in beneficial ownership of securities| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683806&type=HTML&symbol=BLFS&cdn=331f987e7c614a891dc783f01f71d1c1&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683806&type=DOC&symbol=BLFS&cdn=331f987e7c614a891dc783f01f71d1c1&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683806&type=PDF&symbol=BLFS&cdn=331f987e7c614a891dc783f01f71d1c1&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683806&type=XLS&symbol=BLFS&cdn=331f987e7c614a891dc783f01f71d1c1&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)  \n4| Statement of changes in beneficial ownership of securities| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683807&type=HTML&symbol=BLFS&cdn=cc541c8c4c9127228e81007725630cab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683807&type=DOC&symbol=BLFS&cdn=cc541c8c4c9127228e81007725630cab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683807&type=PDF&symbol=BLFS&cdn=cc541c8c4c9127228e81007725630cab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683807&type=XLS&symbol=BLFS&cdn=cc541c8c4c9127228e81007725630cab&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)  \n4| Statement of changes in beneficial ownership of securities| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683810&type=HTML&symbol=BLFS&cdn=f8223c011d9500d9cb95fe12e5adcb12&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683810&type=DOC&symbol=BLFS&cdn=f8223c011d9500d9cb95fe12e5adcb12&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683810&type=PDF&symbol=BLFS&cdn=f8223c011d9500d9cb95fe12e5adcb12&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318683810&type=XLS&symbol=BLFS&cdn=f8223c011d9500d9cb95fe12e5adcb12&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-11-01)  \nSC 13G/A| Amendment to a previously filed SC 13G| Nov 01, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Amendment to a previously filed SC 13G in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318682988&type=HTML&symbol=BLFS&cdn=2c28a4b9ef44fb979acc4cb3d13751fa&companyName=BioLife+Solutions+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_doc.png)Open Amendment to a previously filed SC 13G in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318682988&type=DOC&symbol=BLFS&cdn=2c28a4b9ef44fb979acc4cb3d13751fa&companyName=BioLife+Solutions+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Amendment to a previously filed SC 13G in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318682988&type=PDF&symbol=BLFS&cdn=2c28a4b9ef44fb979acc4cb3d13751fa&companyName=BioLife+Solutions+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-01)[![](images/webdriver/fileicons/16/sec_xls.png)Open Amendment to a previously filed SC 13G in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318682988&type=XLS&symbol=BLFS&companyName=BioLife+Solutions+Inc.&formType=SC+13G%2FA&dateFiled=2024-11-01)  \n4| Statement of changes in beneficial ownership of securities| Oct 17, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318651313&type=HTML&symbol=BLFS&cdn=ee4584b91be9b4cd3fed005dee7e5233&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-10-17)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318651313&type=DOC&symbol=BLFS&cdn=ee4584b91be9b4cd3fed005dee7e5233&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-10-17)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318651313&type=PDF&symbol=BLFS&cdn=ee4584b91be9b4cd3fed005dee7e5233&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-10-17)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318651313&type=XLS&symbol=BLFS&cdn=ee4584b91be9b4cd3fed005dee7e5233&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-10-17)  \n4| Statement of changes in beneficial ownership of securities| Sep 20, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603159&type=HTML&symbol=BLFS&cdn=21c11e8396c6257406f0e0f9b0d9e642&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603159&type=DOC&symbol=BLFS&cdn=21c11e8396c6257406f0e0f9b0d9e642&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603159&type=PDF&symbol=BLFS&cdn=21c11e8396c6257406f0e0f9b0d9e642&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-20)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318603159&type=XLS&symbol=BLFS&cdn=21c11e8396c6257406f0e0f9b0d9e642&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-20)  \n4| Statement of changes in beneficial ownership of securities| Sep 18, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598913&type=HTML&symbol=BLFS&cdn=2914117bdfcdbaceec407b79f3b3e8ed&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598913&type=DOC&symbol=BLFS&cdn=2914117bdfcdbaceec407b79f3b3e8ed&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598913&type=PDF&symbol=BLFS&cdn=2914117bdfcdbaceec407b79f3b3e8ed&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598913&type=XLS&symbol=BLFS&cdn=2914117bdfcdbaceec407b79f3b3e8ed&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)  \n4| Statement of changes in beneficial ownership of securities| Sep 18, 2024| [![](images/webdriver/fileicons/16/sec_html.png)Open Statement of changes in beneficial ownership of securities in HTML.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598912&type=HTML&symbol=BLFS&cdn=99134258d6cfd6dd488f303be0d91589&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_doc.png)Open Statement of changes in beneficial ownership of securities in DOC file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598912&type=DOC&symbol=BLFS&cdn=99134258d6cfd6dd488f303be0d91589&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_pdf.png)Open Statement of changes in beneficial ownership of securities in PDF file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598912&type=PDF&symbol=BLFS&cdn=99134258d6cfd6dd488f303be0d91589&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)[![](images/webdriver/fileicons/16/sec_xls.png)Open Statement of changes in beneficial ownership of securities in XLS file.](https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318598912&type=XLS&symbol=BLFS&cdn=99134258d6cfd6dd488f303be0d91589&companyName=BioLife+Solutions+Inc.&formType=4&dateFiled=2024-09-18)  \n**1-25[26-50](https://investors.biolifesolutions.com/index.php?o=25&s=127) [51-75](https://investors.biolifesolutions.com/index.php?o=50&s=127) [76-100](https://investors.biolifesolutions.com/index.php?o=75&s=127) [101-122](https://investors.biolifesolutions.com/index.php?o=100&s=127)**  \n  \n  * [](#print \"print\")\n  * [](#email \"email\")\n\n\n\n[Trailing 12-Months](https://investors.biolifesolutions.com/SEC-filings?year=)[Calendar Year 2024](https://investors.biolifesolutions.com/SEC-filings?year=2024)[Calendar Year 2023](https://investors.biolifesolutions.com/SEC-filings?year=2023)[Calendar Year 2022](https://investors.biolifesolutions.com/SEC-filings?year=2022)[Calendar Year 2021](https://investors.biolifesolutions.com/SEC-filings?year=2021)[Calendar Year 2020](https://investors.biolifesolutions.com/SEC-filings?year=2020)[Calendar Year 2019](https://investors.biolifesolutions.com/SEC-filings?year=2019)[Calendar Year 2018](https://investors.biolifesolutions.com/SEC-filings?year=2018)[Calendar Year 2017](https://investors.biolifesolutions.com/SEC-filings?year=2017)[Calendar Year 2016](https://investors.biolifesolutions.com/SEC-filings?year=2016)[Calendar Year 2015](https://investors.biolifesolutions.com/SEC-filings?year=2015)[Calendar Year 2014](https://investors.biolifesolutions.com/SEC-filings?year=2014)[Calendar Year 2013](https://investors.biolifesolutions.com/SEC-filings?year=2013)[Calendar Year 2012](https://investors.biolifesolutions.com/SEC-filings?year=2012)[Calendar Year 2011](https://investors.biolifesolutions.com/SEC-filings?year=2011)[Calendar Year 2010](https://investors.biolifesolutions.com/SEC-filings?year=2010)[Calendar Year 2009](https://investors.biolifesolutions.com/SEC-filings?year=2009)[Calendar Year 2008](https://investors.biolifesolutions.com/SEC-filings?year=2008)[Calendar Year 2007](https://investors.biolifesolutions.com/SEC-filings?year=2007)[Calendar Year 2006](https://investors.biolifesolutions.com/SEC-filings?year=2006)[Calendar Year 2005](https://investors.biolifesolutions.com/SEC-filings?year=2005)[Calendar Year 2004](https://investors.biolifesolutions.com/SEC-filings?year=2004)[Calendar Year 2003](https://investors.biolifesolutions.com/SEC-filings?year=2003)[Calendar Year 2002](https://investors.biolifesolutions.com/SEC-filings?year=2002)[Calendar Year 2001](https://investors.biolifesolutions.com/SEC-filings?year=2001)[Calendar Year 2000](https://investors.biolifesolutions.com/SEC-filings?year=2000)[Calendar Year 1999](https://investors.biolifesolutions.com/SEC-filings?year=1999)[Calendar Year 1998](https://investors.biolifesolutions.com/SEC-filings?year=1998)[Calendar Year 1997](https://investors.biolifesolutions.com/SEC-filings?year=1997)[Calendar Year 1996](https://investors.biolifesolutions.com/SEC-filings?year=1996)[Calendar Year 1995](https://investors.biolifesolutions.com/SEC-filings?year=1995)[All Filings](https://investors.biolifesolutions.com/SEC-filings?cat=)[Annual Filings](https://investors.biolifesolutions.com/SEC-filings?cat=1)[Quarterly Filings](https://investors.biolifesolutions.com/SEC-filings?cat=2)[Current Filings](https://investors.biolifesolutions.com/SEC-filings?cat=3)[Registration Statements](https://investors.biolifesolutions.com/SEC-filings?cat=4)[Section 16](https://investors.biolifesolutions.com/SEC-filings?cat=5)[Proxy & Information Statements](https://investors.biolifesolutions.com/SEC-filings?cat=7)[Other](https://investors.biolifesolutions.com/SEC-filings?cat=8)\n"
        }
      ]
    }
  ]
}